All news

Moderna lifts 2026 revenue growth outlook

CNBC · RSS · · AI-summarised by FinFlash

Moderna raised its 2026 revenue outlook, now guiding to growth of 15% to 25%, up from a prior range of up to 10%. The biotech company's CEO said newer vaccines are gaining traction, supporting the upgraded forecast. The higher guidance signals improving commercial momentum beyond the company's original expectations.

Read original source

MRNA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.